We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.68B
1-Year Est. Return 126.09%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+126.09%
3 Year Est. Return
+506.91%
5 Year Est. Return
+511.42%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
+$573M
Cap. Flow
+$403M
Cap. Flow %
23.96%
Top 10 Hldgs %
87.85%
Holding
22
New
2
Increased
2
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
KLRA
Kailera Therapeutics
KLRA
+$496M
2
ALKS icon
Alkermes
ALKS
+$51.9M
3
COAG
Hemab Therapeutics
COAG
+$45.5M
4
CABA icon
Cabaletta Bio
CABA
+$24.9M

Top Sells

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$115M
2
HTFL
Heartflow Inc
HTFL
+$60.1M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$25.2M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$5.2M
5
ANNX icon
Annexon
ANNX
+$4.28M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Miscellaneous 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLRA
1
Kailera Therapeutics
KLRA
$1.55B
$498M 29.58%
+22,583,268
New +$496M
HTFL
2
Heartflow Inc
HTFL
$4.38B
$248M 14.74%
8,448,158
-2,000,000
-19% -$60.1M
NAMS icon
3
NewAmsterdam Pharma
NAMS
$2.7B
$129M 7.67%
3,806,566
-3,500,000
-48% -$115M
SVRA icon
4
Savara
SVRA
$1.12B
$108M 6.45%
17,600,621
– –
ALKS icon
5
Alkermes
ALKS
$7.41B
$102M 6.04%
1,937,938
+1,327,938
+218% +$51.9M
SLDB icon
6
Solid Biosciences
SLDB
$916M
$98M 5.83%
9,808,819
– –
PHVS icon
7
Pharvaris
PHVS
$2.53B
$92.5M 5.5%
2,675,509
– –
OLMA icon
8
Olema Pharmaceuticals
OLMA
$843M
$88.6M 5.27%
7,085,249
-387,989
-5% -$5.2M
COAG
9
Hemab Therapeutics
COAG
$1.77B
$60.6M 3.6%
+1,650,000
New +$45.5M
CABA icon
10
Cabaletta Bio
CABA
$417M
$53.6M 3.19%
17,241,445
+7,564,320
+78% +$24.9M
XFOR icon
11
X4 Pharmaceuticals
XFOR
$347M
$37.2M 2.21%
7,967,454
– –
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.4B
$35.3M 2.1%
362,470
– –
CCCC icon
13
C4 Therapeutics
CCCC
$406M
$33.5M 1.99%
7,171,910
– –
KYTX icon
14
Kyverna Therapeutics
KYTX
$440M
$25.7M 1.53%
2,885,000
-225,000
-7% -$2M
ANNX icon
15
Annexon
ANNX
$800M
$25.3M 1.51%
4,437,731
-774,943
-15% -$4.28M
RPID icon
16
Rapid Micro Biosystems
RPID
$56.7M
$14.6M 0.87%
8,434,560
– –
IRON icon
17
Disc Medicine
IRON
$2.63B
$10.3M 0.61%
141,234
– –
AVIR icon
18
Atea Pharmaceuticals
AVIR
$436M
$9.65M 0.57%
2,075,639
-284,999
-12% -$1.42M
XLO icon
19
Xilio Therapeutics
XLO
$59.4M
$6.36M 0.38%
664,021
– –
UPB
20
Upstream Bio Inc
UPB
$294M
$4.16M 0.25%
600,949
-266,262
-31% -$2.23M
NAMSW icon
21
NewAmsterdam Pharma Warrant
NAMSW
$2.14M 0.13%
99,999
– –
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-635,000
Closed -$25.2M

Similar funds

TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
MCM
Maple Capital Management Montpelier, Vermont $1.68B AUM 27.38% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TNBTD
Trustmark National Bank Trust Department Jackson, Mississippi $1.68B AUM 19.26% 1-Year Est. Return
SH
Spear Holdings Dubai, United Arab Emirates $1.68B AUM 4.3% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2026 Portfolio in Review

As of Q2 2026, Bain Capital Life Sciences Investors held 22 positions worth $1.68B, up 52% from $1.11B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Bain Capital Life Sciences Investors deployed $403M of net new capital in Q2 2026, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Kailera Therapeutics: 22,583,268 shares worth $498M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was NewAmsterdam Pharma, an estimated $115M trimmed.

  • Bain Capital Life Sciences Investors's largest Q2 2026 buy was Kailera Therapeutics: 22,583,268 shares worth $498M.
  • Bain Capital Life Sciences Investors added most to Alkermes in Q2 2026, an estimated $51.9M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2026 reduction was NewAmsterdam Pharma, cutting an estimated $115M.
  • Bain Capital Life Sciences Investors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $25.2M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 88% of its $1.68B portfolio in Q2 2026.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 1 in Q2 2026.
  • Bain Capital Life Sciences Investors's portfolio value rose 52% quarter-over-quarter to $1.68B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.